How to Predict Recurrence After Resection of Hepatocellular Carcinoma.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-01-01 DOI:10.21873/anticanres.17404

Natalie Petruch, Louisa Bolm, Martina Nebbia, Shahrzad Arya, Marco Ventin, Motaz Qadan, Nahel Elias, Jannis Duhn, Dirk Rades, Leigh A Dageforde, Kenneth T Tanabe, Joseph Franses, Vikram Deshpande, Ulrich F Wellner, Tobias Keck, Onofrio Catalano, Cristina R Ferrone

{"title":"How to Predict Recurrence After Resection of Hepatocellular Carcinoma.","authors":"Natalie Petruch, Louisa Bolm, Martina Nebbia, Shahrzad Arya, Marco Ventin, Motaz Qadan, Nahel Elias, Jannis Duhn, Dirk Rades, Leigh A Dageforde, Kenneth T Tanabe, Joseph Franses, Vikram Deshpande, Ulrich F Wellner, Tobias Keck, Onofrio Catalano, Cristina R Ferrone","doi":"10.21873/anticanres.17404","DOIUrl":null,"url":null,"abstract":"Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation.Patients and methods: In 297 patients undergoing resection of HCC between 2000 and 2021, risk scores and potential additional risk factors for intrahepatic and extrahepatic recurrence were assessed.Results: Median overall survival was 48.4 months, median time to recurrence 25.1 months. The Alpha-Fetoprotein (AFP)-score differentiated between low and high-risk groups (21.8 vs. 8.3 months, p=0.001), as did the Risk Estimation of Tumor Recurrence After Transplant (RETREAT)-score (16 vs. 9 months, p=0.004) and the Clinical Risk Score (CRS) (14.9 vs. 3.9 months, p=0.002). Advanced T-stage, multiple lesions, and vessel infiltration were significantly associated with any type of recurrence, advanced T-stage, and multiple lesions with intrahepatic recurrence.Conclusion: Predictors of recurrence following resection of HCC were identified. Prognostic scores traditionally used for patients receiving liver transplantation (AFP-score, RETREAT-score, CRS) were predictive also of recurrence after resection of HCC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"189-199"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17404","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation.

Patients and methods: In 297 patients undergoing resection of HCC between 2000 and 2021, risk scores and potential additional risk factors for intrahepatic and extrahepatic recurrence were assessed.

Results: Median overall survival was 48.4 months, median time to recurrence 25.1 months. The Alpha-Fetoprotein (AFP)-score differentiated between low and high-risk groups (21.8 vs. 8.3 months, p=0.001), as did the Risk Estimation of Tumor Recurrence After Transplant (RETREAT)-score (16 vs. 9 months, p=0.004) and the Clinical Risk Score (CRS) (14.9 vs. 3.9 months, p=0.002). Advanced T-stage, multiple lesions, and vessel infiltration were significantly associated with any type of recurrence, advanced T-stage, and multiple lesions with intrahepatic recurrence.

Conclusion: Predictors of recurrence following resection of HCC were identified. Prognostic scores traditionally used for patients receiving liver transplantation (AFP-score, RETREAT-score, CRS) were predictive also of recurrence after resection of HCC.

查看原文本刊更多论文

如何预测肝细胞癌切除术后复发。

背景/目的：肝细胞癌（HCC）切除术后复发的预测因素尚未完全确定。本研究调查了这种情况的潜在危险因素和预后评分。患者和方法：在2000年至2021年间接受HCC切除术的297例患者中，评估了肝内和肝外复发的风险评分和潜在的其他危险因素。结果：中位总生存期为48.4个月，中位复发时间为25.1个月。甲胎蛋白（AFP）评分在低高危组之间存在差异（21.8个月vs 8.3个月，p=0.001），移植后肿瘤复发风险评估（RETREAT）评分（16个月vs 9个月，p=0.004）和临床风险评分（CRS）（14.9个月vs 3.9个月，p=0.002）也存在差异。晚期t期、多发病变和血管浸润与任何类型的复发、晚期t期和多发病变伴肝内复发显著相关。结论：确定了肝癌切除术后复发的预测因素。传统上用于肝移植患者的预后评分（afp评分、retreat评分、CRS）也可预测HCC切除术后的复发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.